Why is unfractionated heparin able to inactivate thrombin directly, while low molecular weight heparin acts predominantly on factor Xa?
Choose an answer, then check it.
Clinical Pharmacology · Anticoagulants and Antiplatelets
Heparins
On this page 6 sections
In 30 seconds
Heparins are injectable anticoagulants that work by supercharging the body's own brake pedal on clotting, a protein called antithrombin. Unfractionated heparin (UFH) is short, fast, and unpredictable enough to need frequent blood monitoring, while low molecular weight heparins (LMWH, like enoxaparin) and fondaparinux are more predictable and generally do not need routine monitoring. They all treat and prevent blood clots, but they carry real risks: bleeding and heparin-induced thrombocytopenia (HIT), a dangerous immune reaction that paradoxically causes clotting rather than bruising. Knowing which drug is which — and how each is reversed — is a core nursing safety skill.
The college version
How heparins work
All heparins act indirectly. They do not attack clotting factors themselves; instead, they bind to antithrombin, a naturally occurring protein that slowly inactivates clotting factors, and dramatically speed up its action. The difference between the heparin drugs comes down to molecule size and which clotting factors that antithrombin complex can reach.
Unfractionated heparin is a long, unrefined chain of sugar-like molecules. It is long enough to do two things: it binds antithrombin and also physically bridges antithrombin to thrombin (factor IIa), forming a three-part complex that neutralizes thrombin directly, while also boosting antithrombin's inhibition of factor Xa. Because it hits both thrombin and factor Xa, and because its chains vary widely in length and bind unpredictably to plasma proteins and cells, its anticoagulant effect varies from patient to patient and even hour to hour.
Low molecular weight heparins are made by breaking UFH into shorter fragments. Most of these shorter chains are too short to bridge antithrombin to thrombin, so LMWHs act predominantly by enhancing antithrombin's inhibition of factor Xa, with only modest anti-thrombin activity. This narrower, more selective action produces a more predictable, dose-dependent response.
Fondaparinux takes this idea to its logical endpoint: it is a small, synthetic sugar that binds antithrombin and enhances only its inhibition of factor Xa, with no direct effect on thrombin (factor IIa) at all. It is the purest indirect factor Xa inhibitor in this family.
Route, monitoring, and clearance
UFH can be given intravenously for rapid, titratable systemic anticoagulation, or given subcutaneously for prophylaxis. Because its effect is unpredictable, it requires routine monitoring, historically with activated partial thromboplastin time (aPTT), or with an anti-factor Xa assay in institutions that prefer it, so the infusion can be adjusted up or down. UFH is cleared partly by the body's cells and partly by the kidneys, giving it a short half-life, which is actually an advantage in patients who need anticoagulation switched off quickly, such as before surgery.
LMWHs are given subcutaneously and have a longer, more predictable half-life, allowing scheduled dosing without routine coagulation monitoring for most patients. However, LMWHs are cleared primarily by the kidneys, so patients with significant renal impairment accumulate the drug and need dose adjustment, and in some cases anti-factor Xa monitoring is used to guide dosing in special populations such as renal impairment, pregnancy, or extremes of body weight.
Fondaparinux is also given subcutaneously, has a longer half-life than either UFH or LMWH allowing once-daily dosing, and is renally cleared almost entirely unchanged. This makes it contraindicated in significant renal impairment, where it can accumulate to dangerous levels.
Indications
As a group, heparins are used for prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism), management of acute coronary syndromes, "bridging" anticoagulation when a patient must temporarily stop a longer-acting oral anticoagulant like warfarin (for example, around a surgery), and anticoagulation of extracorporeal circuits such as dialysis or cardiopulmonary bypass, a role that specifically depends on UFH's fast onset and easy reversibility.
Adverse effects
Bleeding is the primary risk with any heparin, from bruising to major hemorrhage. Heparin-induced thrombocytopenia is a distinct and dangerous immune-mediated reaction in which antibodies form against a complex of heparin and platelet factor 4, activating platelets and consuming them. This produces a falling platelet count paired paradoxically with a high risk of new clot formation, arterial or venous, rather than bleeding. HIT can occur with UFH or LMWH, though it is less common with LMWH. The moment HIT is suspected, every heparin source must be stopped immediately, including flushes and heparin-coated catheters, and replaced with a non-heparin anticoagulant such as argatroban or bivalirudin, direct thrombin inhibitors that do not cross-react with the antibody. Long-term heparin use, most notably UFH, is also associated with osteoporosis, and heparins can occasionally cause hyperkalemia by suppressing aldosterone secretion from the adrenal gland.
Reversal
Protamine sulfate, a positively charged protein, binds the negatively charged heparin molecule and neutralizes it. It reverses UFH almost completely. Because LMWH's shorter chains bind protamine less effectively, reversal is only partial. Fondaparinux's small, uniform structure does not bind protamine at all, so protamine has no meaningful reversal effect on it, leaving supportive care and specific reversal agents (where available) as the main options.
Boxed warning: neuraxial procedures
All heparins carry a boxed warning about spinal or epidural hematoma when used around neuraxial procedures such as epidural anesthesia or lumbar puncture, particularly with indwelling epidural catheters or concurrent use of other drugs affecting clotting. Such a hematoma can compress the spinal cord and cause lasting paralysis, so timing of doses around these procedures is carefully coordinated with anesthesia and surgical teams.
Nursing considerations
Subcutaneous heparins are injected into the abdominal fatty tissue, away from the umbilicus, with sites rotated to reduce bruising and lipohypertrophy. The needle is inserted at the instructed angle, and the nurse should never aspirate before injecting or massage the site afterward, since both actions increase local bruising and bleeding into the tissue. Patients on any heparin need bleeding precautions: watching for unusual bruising, blood in urine or stool, gum bleeding, and using soft toothbrushes and electric razors, along with cautious use of other drugs that increase bleeding risk.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine your blood has a tiny guard called antithrombin whose job is to stop clots from growing too big. Heparin is like a coach that grabs the guard and makes it work much faster. Regular heparin (UFH) is a long rope that can grab two troublemakers at once (thrombin and factor Xa), but ropes come in all different lengths, so nobody's totally sure how strong the effect will be — that's why nurses keep checking blood tests. LMWH is a shorter rope that mostly only grabs one troublemaker (factor Xa), so it works more predictably and needs fewer checks. Fondaparinux is a tiny, exact-sized piece that only ever grabs that one troublemaker, nothing else.
Sometimes a patient's body gets confused and starts attacking its own clot-fighting cells (platelets) because of the heparin — that's HIT, and weirdly it makes clots more likely, not bleeding. When that happens, all heparin has to stop right away and a totally different medicine takes over. There's also a rescue medicine, protamine, that can turn off regular heparin like a switch, but it barely works on the short rope and doesn't work at all on the tiny exact piece.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A nurse is about to give a scheduled subcutaneous LMWH injection. Describe two technique points that reduce bruising and bleeding at the injection site.
Show answer
(short answer)
Good answers include: never aspirate before injecting and never massage the site afterward, since both increase bruising; rotate injection sites around the abdomen away from the navel and away from scars or bruises; and inject into the fatty tissue at the recommended angle without rubbing the skin first.
A patient has been receiving an intravenous UFH infusion and is scheduled for emergency surgery within the hour. Explain why UFH's monitoring and reversal profile make it a reasonable choice compared with LMWH in this situation.
Show answer
(short answer)
UFH's effect is easy to monitor in real time and it has a short half-life, so stopping the infusion lets its effect fade quickly, and protamine sulfate can reverse it almost completely if immediate reversal is needed before surgery. LMWH's longer, less reversible effect and lack of routine real-time monitoring make it harder to turn off quickly before an urgent procedure.
Quick check
3 questions here. Answers stay hidden until you check.
A patient with significant renal impairment needs anticoagulation. Which statement is most accurate?
Choose an answer, then check it.
A patient on heparin develops a dropping platelet count along with a new leg clot several days into therapy. What is the priority action?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.